References
  1. Kropeit D, Scheuenpflug J, Erb-Zohar K, Halabi A, Stobernack HP, Hulskotte EGJ, van Schanke A, Zimmermann H, Rübsamen-Schaeff H. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment. Br J Clin Pharmacol . 2017;83(12):2678-2686.
  2. Kropeit D, McCormick D, Erb-Zohar K, Moiseev VS, Kobalava ZD, Stobernack HP, Zimmermann H, Rübsamen-Schaeff H. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. Br J Clin Pharmacol . 2017;83(9):1944-1953.
  3. Kobie J, Guo Z, Cho CR, Menzel K, McCrea JB, Blanchard R, Shaw PMPharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies. J Clin Pharmacol . 2019;59(9):1236-1243.
  4. Royston L, Masouridi-Levrat S, Gotta V, Royston E, Pressacco-Brossier C, Abi Aad Y, Tonoli D, Karmime A, Jayo M, Van Delden C, Lescuyer P, Pfister M, Chalandon Y, Neofytos D. Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Antimicrob Agents Chemother.2022;;66(8):e0065722.
  5. Menzel K, Kothare P, McCrea JB, Chu X, Kropeit D. Absorption, Metabolism, Distribution, and Excretion of Letermovir. Curr Drug Metab . 2021;22(10):784-794.
  6. Isberner N, Aghai F, Schirmer D, et al. Determination of Letermovir Serum Levels Can Be Useful in High-Risk Clinical Settings. J Pediatric Infect Dis Soc . 2020;9(3):402-403.
  7. Isberner N, Aghai F, Schirmer D, Kraus S, Grigoleit GU, Klinker H. Quantification of letermovir in human serum using high-performance liquid chromatography with diode array detection. J Chromatogr B Analyt Technol Biomed Life Sci . 2020;1159:122399.
  8. Isberner N, Aghai F, Schirmer D, Bolz M, Kraus S, Grigoleit GU, Klinker H. Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy. J Antimicrob Chemother . 2021;76(12):3322-3325.
  9. McCrea JB, Macha S, Adedoyin A, Marshall W, Menzel K, Cho CR, Liu F, Zhao T, Levine V, Kraft WK, Yoon E, Panebianco D, Stoch SA, Iwamoto M. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. J Clin Pharmacol . 2019;59(10):1331-1339.
  10. Adedoyin A, Fancourt C, Menzel K, Zhao T, Tomek C, Panebianco D, McCrea JB, Stoch SA, Iwamoto M. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants. Clin Pharmacol Drug Dev. 2021;10(2):198-206.
Table I. List of the medications prescribed before the development of lactic acidosis.
Figure 1. Evolution of lactic acidosis over time.
Figure 2. Pharmacokinetics of letermovir, first sample obtained one hour before the start of continuous venonevous hemofiltration and 18 hours after the last oral administration.